There has been an influx of novel agents in the field of chronic lymphocytic leukemia (CLL) in recent years. These include venetoclax, ibrutinib and obinutuzumab. In this video, recorded at the 23rd Congress of the European Haematology Association (EHA) 2018, held in Stockholm, Sweden, Michael Hallek, PhD, of CECAD Cologne, Cologne, Germany, discusses how these novel agents have transformed CLL treatment. He emphasizes the huge potential for novel agent combination therapies to improve the future treatment of CLL, pointing out incredible response and MRD negativity rates from recent clinical trials.
Novel agent combinations: the future of CLL
